Dose-dependent targeting of 89Zr-labeled atezolizumab (anti-PD-L1 antibody) to PD-L1 expressing tumor xenografts

被引：0
|
作者：
Longtine, Mark [1 ]
Wahl, Richard [1 ]
机构：
[1] Mallinckrodt Inst Radiol, St Louis, MO USA
来源：
JOURNAL OF NUCLEAR MEDICINE | 2018年 / 59卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
1105
引用
收藏
页数：2
相关论文
共 50 条
  • [1] 89Zr-Labeled Anti-PD-L1 Antibody PET Monitors Gemcitabine Therapy-Induced Modulation of Tumor PD-L1 Expression
    Jung, Kyung-Ho
    Park, Jin Won
    Lee, Jin Hee
    Moon, Seung Hwan
    Cho, Young Seok
    Lee, Kyung-Han
    JOURNAL OF NUCLEAR MEDICINE, 2021, 62 (05) : 656 - 664
  • [2] Optimizing Immuno-PET Imaging of Tumor PD-L1 Expression: Pharmacokinetic, Biodistribution, and Dosimetric Comparisons of 89Zr-Labeled Anti-PD-L1 Antibody Formats
    Bouleau, Alizee
    Nozach, Herve
    Dubois, Steven
    Kereselidze, Dimitri
    Chevaleyre, Celine
    Wang, Cheng-, I
    Evans, Michael J.
    Lebon, Vincent
    Maillere, Bernard
    Truillet, Charles
    JOURNAL OF NUCLEAR MEDICINE, 2022, 63 (08) : 1259 - 1265
  • [3] Imaging of PD-L1 modulation by gemcitabine using 89Zr labeled anti-PD-L1 antibody PET.
    Jung, Kyung-Ho
    Park, Jin Won
    Lee, Jin Hee
    Cho, Young Seok
    Lee, Kyung-Han
    CANCER IMMUNOLOGY RESEARCH, 2020, 8 (03) : 90 - 91
  • [4] 89Zr-Labeled Anti-PD-L1 Antibody Fragment for EvaluatingIn VivoPD-L1 Levels in Melanoma Mouse Model
    Bridgwater, Caleb
    Geller, Anne
    Hu, Xiaoling
    Burlison, Joe A.
    Zhang, Huang-Ge
    Yan, Jun
    Guo, Haixun
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2020, 35 (08) : 549 - 557
  • [5] Product review on the Anti-PD-L1 antibody atezolizumab
    Shah, Neil J.
    Kelly, William J.
    Liu, Stephen V.
    Choquette, Karin
    Spira, Alexander
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2018, 14 (02) : 269 - 276
  • [6] Immuno-PET Imaging of 89Zr Labeled Anti-PD-L1 Domain Antibody
    Li, Dan
    Cheng, Siyuan
    Zou, Sijuan
    Zhu, Dongling
    Zhu, Tinghui
    Wang, Pilin
    Zhu, Xiaohua
    MOLECULAR PHARMACEUTICS, 2018, 15 (04) : 1674 - 1681
  • [7] Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
    Lee, Hyun Tae
    Lee, Ju Yeon
    Lim, Heejin
    Lee, Sang Hyung
    Moon, Yu Jeong
    Pyo, Hyo Jeong
    Ryu, Seong Eon
    Shin, Woori
    Heo, Yong-Seok
    SCIENTIFIC REPORTS, 2017, 7
  • [8] Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
    Hyun Tae Lee
    Ju Yeon Lee
    Heejin Lim
    Sang Hyung Lee
    Yu Jeong Moon
    Hyo Jeong Pyo
    Seong Eon Ryu
    Woori Shin
    Yong-Seok Heo
    Scientific Reports, 7
  • [9] Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1)
    Kowanetz, Marcin
    Zou, Wei
    Gettinger, Scott N.
    Koeppen, Hartmut
    Kockx, Mark
    Schmid, Peter
    Kadel, Edward E., III
    Wistuba, Ignacio
    Chaft, Jamie
    Rizvi, Naiyer A.
    Spigel, David R.
    Spira, Alexander
    Hirsch, Fred R.
    Cohen, Victor
    Smith, Dustin
    Boyd, Zach
    Miley, Natasha
    Flynn, Susan
    Leveque, Vincent
    Shames, David S.
    Ballinger, Marcus
    Mocci, Simonetta
    Shankar, Geetha
    Funke, Roel
    Hampton, Garret
    Sandler, Alan
    Amler, Lukas
    Mellman, Ira
    Chen, Daniel S.
    Hegde, Priti S.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2018, 115 (43) : E10119 - E10126
  • [10] Structural basis of the therapeutic anti-PD-L1 antibody atezolizumab
    Zhang, Fei
    Qi, Xiaoqiang
    Wang, Xiaoxiao
    Wei, Diyang
    Wu, Jiawei
    Feng, Lingling
    Cai, Haiyan
    Wang, Yugang
    Zeng, Naiyan
    Xu, Ting
    Zhou, Aiwu
    Zheng, Ying
    ONCOTARGET, 2017, 8 (52) : 90215 - 90224
12345